debate: best approach for multiple relapsed cll after chemoimmunotherapy - kinase inhibitor
Published 9 years ago • 83 plays • Length 11:23Download video MP4
Download video MP3
Similar videos
-
19:14
debate: best approach for multiple relapsed cll after chemoimmunotherapy - other novel agents
-
14:03
debate: best approach for multiple relapsed cll after chemoimmunotherapy - asct
-
13:55
debate: optimal approach for the management of cll patients with del(17p) - novel agents
-
14:21
debate: which is the optimal approach for cll? - fcr
-
21:19
cll: sequencing monotherapy vs. combination therapy
-
16:07
treatment strategies for relapsed/refractory cll
-
11:45
debate: relapsed mantle cell lymphoma - ibrutinib based therapy alone
-
12:08
debate: which is the optimal approach for cll? - br
-
14:48
debate: best frontline regimen for a cll patient aged 60 who requires therapy - ibrutinib
-
25:38
cll: chemotherapy and ibrutinib based regimens
-
14:13
debate: do we have enough data to eliminate chemotherapy from initial treatment for cll? - yes
-
14:02
debate: best frontline regimen for a cll patient aged 60 who requires therapy - fcr
-
0:48
advances in non-covalent btk inhibitors for cll: bruin study update
-
35:31
cll: btk inhibitors in hematologic oncology pathways - pathway-guided choices
-
19:42
treatment options for the young cll patient with deletion 17p: do they need a different approach?
-
3:45
therapeutic approach for cll relapse
-
12:59
debate: do we have enough data to eliminate chemotherapy from initial treatment for cll? - no
-
21:19
other new molecules in the cll pipeline: pi3k inhibitors, syk inhibitors, etc.
-
15:23
debate: optimal approach for the management of cll patients with del(17p) - ibrutinib